WASHINGTON — Drug companies are routinely flouting a law requiring that they publicly disclose detailed policies on how they handle patient requests to provide access to experimental drugs outside clinical trials, according to a STAT review.

A provision in the 21st Century Cures Act said drug makers must disclose their policies on so-called expanded access requests, which are generally made by terminally ill patients. The language doesn’t force companies to offer the experimental treatments, but it does aim to help patients navigate the system more easily — making readily available information including whether companies accepts the requests, who a patient can contact in such cases, and how long it typically takes the drug maker to respond.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy